Clinical Cancer Drugs
Volume 6, 2 Issues, 2019
ISSN: 2212-6988 (Online)
ISSN: 2212-697X (Print)
This journal supports open access
ISSN: 2212-6988 (Online)
ISSN: 2212-697X (Print)
This journal supports open access
Aims & Scope
Clinical Cancer Drugs publishes original research, full-length reviews/ mini reviews, and thematic issues in all core areas of translational and clinical cancer drug research.
The journal publishes pre-clinical and clinical studies on the development of new anti-cancer agents. Clinical studies of new reported anti-cancer drugs include Phase 1–IV clinical trial studies, their designs, research methodologies, and analyses. The journal is essential reading for clinical oncologists, toxicologists, medicinal chemists, and pharmacologists.
Clinical Cancer Drugs
,Volume 5
-Number 2
Biography Open Access
Meet Our Editor-in-Chief
Review Article Open Access
New Robotic Technologies in Cancer Colon Screening
, 5(2): 68 - 74Luigi Manfredi* and Gianfranco Natale
DOI: 10.2174/2212697X06666181220130020
New Robotic Technologies in Cancer Colon Screening
Review Article Open Access
May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients?
, 5(2): 75 - 86Riccardo Presciuttini, Romano Danesi and Guido Bocci*
DOI: 10.2174/2212697X06666181219095936
May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients?
Review Article Open Access
Erlotinib in Non-Small Cell Lung Cancer: From a thought to Necessity
, 5(2): 87 - 93Parijat Pandey and Harish Dureja*
DOI: 10.2174/2212697X06666190102110412
Erlotinib in Non-Small Cell Lung Cancer: From a thought to Necessity
Research Article Open Access
Computational Analysis of the Binding Site(s) of TNF β-TNFR1 Complex: Implications for Designing Novel Anticancer Agents
, 5(2): 94 - 104Trupti Kashinath Khatal and Ganesh Ulhasrao Chaturbhuj*
DOI: 10.2174/2212697X06666181126111445
Computational Analysis of the Binding Site(s) of TNF β-TNFR1 Complex: Implications for Designing Novel Anticancer Agents
Research Article Open Access
Formulation and Evaluation of pH Sensitive Sustained Release Hydrogel of Methotrexate
, 5(2): 105 - 112Swatantra Kumar Singh Kushwaha*, Prashant Kumar and Awani Kumar Rai
DOI: 10.2174/2212697X06666190102105652
Formulation and Evaluation of pH Sensitive Sustained Release Hydrogel of Methotrexate
Research Article Open Access
Effects of Lysozyme on Ehrlich Ascites Carcinoma Cells: The Possible Physiological Role of Lysozyme in the Prevention of Carcinogenesis
, 5(2): 113 - 118Vardan K. Gasparyan*, Hayk A. Harutyunyan, Mariam V. Mikaelyan and Gayane G. Poghosyan
DOI: 10.2174/2212697X06666190110120026
Effects of Lysozyme on Ehrlich Ascites Carcinoma Cells: The Possible Physiological Role of Lysozyme in the Prevention of Carcinogenesis
Acknowledgement Open Access
Acknowledgements to Reviewers
Articles Ahead of Print
A Marine-based Meriolin (3-Pyrimidinylazaindole) Derivative (4ab) Targets PI3K/AKT /mTOR Pathway Inducing Cell Cycle Arrest and Apoptosis in Molt-4 Cells
Gousia Chashoo*, Umed Singh, Parvinder Pal Singh, Dilip M. Mondhe and Ram A. Vishwakarma
View Abstract
Withdrawn: Intraoperative Sono-photodynamic Therapy for Anaplastic Astrocytoma Grade III With Transformation in Glioblastoma Grade IV
Dmitry Tzerkovsky*, Fedor Borichevsky, Yuri Grachev and Yuri Istomin
View Abstract
Novel Molecular Targets and Mechanisms Involved in the Invasion and Metastasis of Pancreatic Cancer
Ziyi Li, Weidong Li, Yuqi Dong and Xueying Sun*
View Abstract
Targeting Breast Cancer Stem Cells (BCSCs) with Liposomal Formulations
Sumayah Al-Mahmood*
View Abstract
Evaluation of Fibrolytic Effect of Bauhinia purpurea L.
Jeevan Ranjan Dash, Tapas Kumar Sar*, Rinku Buragohain, Indranil Samanta and Rahul Nanotkar
View Abstract
Abstracts Ahead of Print
Halogen directed drug design of Ginsenoside for the treatment of Cancer: A Combined Density Functional and Molecular Docking Study
Sajal Biswas, Abul Bashar Ripon Khalipha, Md. Solayman Hossain* and Pranta Ray
View Abstract
Published Contents
Editor's Choice
Effects of Lysozyme on Ehrlich Ascites Carcinoma Cells: The Possible Physiological Role of Lysozyme in the Prevention of Carcinogenesis
, 2018; 5(2): 113 - 118Vardan K. Gasparyan*, Hayk A. Harutyunyan, Mariam V. Mikaelyan and Gayane G. Poghosyan
DOI: 10.2174/2212697X06666190110120026
Arachidonic Acid Induces the Migration of MDA-MB-231 Cells by Activating Raft-associated Leukotriene B4 Receptors
, 2018; 5(1): 28 - 41Atasi De Chatterjee, Debarshi Roy, Priscilla Guevara, Rituraj Pal, Mahesh Narayan, Sukla Roychowdhury and Siddhartha Das*
DOI: 10.2174/2212697X05666180418145601
Prevalence of Neuropathy Associated With Bortezomib: A Retrospective Study
, 2017; 4(1): 69 - 72Pulivarthi Swaroopa, Mathew Josy, Ehresmann Kirsten and Gurram Murali Krishna*
DOI: 10.2174/2212697X03666161128102453
Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors
, 2016; 3(2): 131 - 137G. Steven Martinez, Jeremy A. Ross and Robert A. Kirken
DOI: 10.2174/2212697X03666160610085943
A Single Center Phase II Study of Continuous Infusion of Low-dose 5- fluorouracil for Heavily Pretreated Patients With Metastatic Colorectal Cancer
, 2015; 2(2): 87 - 90Hong-tao Chen, Yi-feng Liao, Mei Xiao, Lin Ma and Hong-Yu Zhang
DOI: 10.2174/2212697X02666151026215656
Inhibition of Autophagy by Targeting ATG4B: Promises and Challenges of An Emerging Anti-cancer Strategy
, 2015; 2(1): 61 - 70Kelly Lien, Michelle Rocha, Elisa Tran, Van C. Hoang, Annabelle Chow and Urban Emmenegger
DOI: 10.2174/2212697X02666150331202809
Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy
, 2014; 1(2): 116 - 126Annabelle Chow, Giulio Francia, Andrew Kouri, Christina Lee, John M. Ebos, Robert S. Kerbel and Urban Emmenegger
DOI: 10.2174/2212697X01666131218235200
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment
, 2014; 1(1): 65 - 71Bianca Maria Veneziani, Micaela Montanari, Maria Letizia Cataldo, Luigi Coppola, Agostina Nardone, Sara Corvigno, Carmine De Angelis, Grazia Arpino, Mario Giuliano, Chiara Carlomagno, Roberto Bianco and Sabino De Placido
DOI: 10.2174/2212697X113016660008
Open Access Articles
Evaluation of Fibrolytic Effect of Bauhinia purpurea L.
, 2019; 6: 1 - 12 (E-Pub Ahead of Print)Jeevan Ranjan Dash, Tapas Kumar Sar*, Rinku Buragohain, Indranil Samanta and Rahul Nanotkar
Targeting Breast Cancer Stem Cells (BCSCs) with Liposomal Formulations
, 2019; 6: 1 - 5 (E-Pub Ahead of Print)Sumayah Al-Mahmood*
Novel Molecular Targets and Mechanisms Involved in the Invasion and Metastasis of Pancreatic Cancer
, 2019; 6: 1 - 13 (E-Pub Ahead of Print)Ziyi Li, Weidong Li, Yuqi Dong and Xueying Sun*
A Marine-based Meriolin (3-Pyrimidinylazaindole) Derivative (4ab) Targets PI3K/AKT /mTOR Pathway Inducing Cell Cycle Arrest and Apoptosis in Molt-4 Cells
, 2019; 6: 1 - 8 (E-Pub Ahead of Print)Gousia Chashoo*, Umed Singh, Parvinder Pal Singh, Dilip M. Mondhe and Ram A. Vishwakarma
Computational Analysis of the Binding Site(s) of TNF β-TNFR1 Complex: Implications for Designing Novel Anticancer Agents
, 2018; 5(2): 94 - 104Trupti Kashinath Khatal and Ganesh Ulhasrao Chaturbhuj*
Erlotinib in Non-Small Cell Lung Cancer: From a thought to Necessity
, 2018; 5(2): 87 - 93Parijat Pandey and Harish Dureja*
May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients?
, 2018; 5(2): 75 - 86Riccardo Presciuttini, Romano Danesi and Guido Bocci*
New Robotic Technologies in Cancer Colon Screening
, 2018; 5(2): 68 - 74Luigi Manfredi* and Gianfranco Natale
Effects of Lysozyme on Ehrlich Ascites Carcinoma Cells: The Possible Physiological Role of Lysozyme in the Prevention of Carcinogenesis
, 2018; 5(2): 113 - 118Vardan K. Gasparyan*, Hayk A. Harutyunyan, Mariam V. Mikaelyan and Gayane G. Poghosyan
Formulation and Evaluation of pH Sensitive Sustained Release Hydrogel of Methotrexate
, 2018; 5(2): 105 - 112Swatantra Kumar Singh Kushwaha*, Prashant Kumar and Awani Kumar Rai
Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
, 2016; 3(2): 76 - 86Xiao-Yan Zhao, Babu Subramanyam, Nenad Sarapa, Sven Golfier and Harald Dinter
Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors
, 2016; 3(2): 131 - 137G. Steven Martinez, Jeremy A. Ross and Robert A. Kirken
A Single Center Phase II Study of Continuous Infusion of Low-dose 5- fluorouracil for Heavily Pretreated Patients With Metastatic Colorectal Cancer
, 2015; 2(2): 87 - 90Hong-tao Chen, Yi-feng Liao, Mei Xiao, Lin Ma and Hong-Yu Zhang
The Importance of Lamivudine Therapy in Liver Cirrhosis Patients Related HBV with Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy
, 2015; 2(2): 112 - 118Koichi Momiyama, Hidenari Nagai, Yu Ogino, Takanori Mukouzu, Daigo Matsui, Michio Kogame, Teppei Matsui, Noritaka Wakui, Mie Shinohara, Yoshinori Igarashi and Yasukiyo Sumino
Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies
, 2015; 2(2): 100 - 111Benny Johnson and Daruka Mahadevan
Most Cited Articles
Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 1 – Where Do We Stand?
, 2017; 4(2): 74-81.Manon Launay, Joseph Ciccolini*, Anne Rodallec, Claire Fournel, Florence Duffaud, Sebastien Salas and Bruno Lacarelle
DOI: 10.2174/2212697X04666170531080625
The PI3K/AKT/mTOR-Signal Transduction Pathway as Drug Target in Triple-Negative Breast Cancer
, 2017; 4(1): 47-58.Jens C. Hahne*, Jorg B. Engel, Arnd Honig, Susanne R. Meyer, Domenico Zito, Andrea Lampis and Nicola Valeri
DOI: 10.2174/2212697X04666170321112629
Intra-arterial Temozolomide, Osmotic Blood-brain Barrier Disruption and Radiotherapy in a Rat F98-Glioma Model
, 2017; 4(2): 135-144.Annie I. Drapeau, Marie-Belle Poirier, Guru-Swamy Madugundu, J. Richard Wagner and David Fortin*
DOI: 10.2174/2212697X04666170727152212
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World
, 2017; 4(2): 82-92.Antonello Di Paolo*, Marzia Del Re, Elena Arrigoni, Teresa Di Desidero, Eleonora Rofi, Romano Danesi and Guido Bocci
DOI: 10.2174/2212697X04666170817124625
Most Accessed Articles
Computational Analysis of the Binding Site(s) of TNF β-TNFR1 Complex: Implications for Designing Novel Anticancer Agents
, 2018; 5(2): 94-104.Trupti Kashinath Khatal and Ganesh Ulhasrao Chaturbhuj*
DOI: 10.2174/2212697X06666181126111445
May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients?
, 2018; 5(2): 75-86.Riccardo Presciuttini, Romano Danesi and Guido Bocci*
DOI: 10.2174/2212697X06666181219095936
Formulation and Evaluation of pH Sensitive Sustained Release Hydrogel of Methotrexate
, 2018; 5(2): 105-112.Swatantra Kumar Singh Kushwaha*, Prashant Kumar and Awani Kumar Rai
DOI: 10.2174/2212697X06666190102105652
Erlotinib in Non-Small Cell Lung Cancer: From a thought to Necessity
, 2018; 5(2): 87-93.Parijat Pandey and Harish Dureja*
DOI: 10.2174/2212697X06666190102110412
Effects of Lysozyme on Ehrlich Ascites Carcinoma Cells: The Possible Physiological Role of Lysozyme in the Prevention of Carcinogenesis
, 2018; 5(2): 113-118.Vardan K. Gasparyan*, Hayk A. Harutyunyan, Mariam V. Mikaelyan and Gayane G. Poghosyan
DOI: 10.2174/2212697X06666190110120026
New Robotic Technologies in Cancer Colon Screening
, 2018; 5(2): 68-74.Luigi Manfredi* and Gianfranco Natale
DOI: 10.2174/2212697X06666181220130020
Inhibition of Autophagy by Targeting ATG4B: Promises and Challenges of An Emerging Anti-cancer Strategy
, 2015; 2(1): 61-70.Kelly Lien, Michelle Rocha, Elisa Tran, Van C. Hoang, Annabelle Chow and Urban Emmenegger
DOI: 10.2174/2212697X02666150331202809
Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment
, 2015; 2(1): 4-15.Mizue Terai and Takami Sato
DOI: 10.2174/2212697X02666150203212041
  |
Editor-in-Chief
Giulio Francia
The University of Texas
El Paso, TX
USA
Biography
View Full Editorial Board
The University of Texas
El Paso, TX
USA
Biography
Biography of Giulio Francia
Dr. Francia began his career by undertaking a PhD with Dr. Ian Hart at the Imperial Cancer Research Fund in London, UK, which has since evolved into Cancer UK. After his PhD, he trained with Dr. Robert Kerbel in Toronto, Canada, on aspects of metastasis, therapies for metastatic disease, and tumor resistance to therapy. He is now Assistant Professor at The University of Texas at El Paso, where he is attempting to set up a research program that is internationally recognized for pioneering new cancer therapeutic ideas, and for generating in vivo models to help translate laboratory findings into the clinic - by developing new metastatic tumor models, and by refining those he has already established.
About the Journal
For Authors
For Librarians & Readers
Journal History
Clinical Cancer Drugs was introduced in 2014 with the assistance of Dr. Giulio Francia, who is the current Editor-in-Chief serving since 2014.
Webmaster Contact: info@benthamscience.net